{
  "subset": "indication",
  "disease": "Neonatal cholestasis",
  "relation": "indication",
  "gold_drugs": [
    "lum001",
    "odevixibat"
  ],
  "seeds_initial": [
    "Ursodiol",
    "Actigall",
    "TUDCA",
    "S-adenosylmethionine",
    "Cholic acid",
    "Hazar",
    "Ocaliva",
    "Xymed",
    "Entrytrade",
    "Zanolimid",
    "Emproof",
    "Dexamethasone"
  ],
  "seed_history": [
    [
      "Ursodiol",
      "Actigall",
      "TUDCA",
      "S-adenosylmethionine",
      "Cholic acid",
      "Hazar",
      "Ocaliva",
      "Xymed",
      "Entrytrade",
      "Zanolimid",
      "Emproof",
      "Dexamethasone"
    ]
  ],
  "final_report": {
    "final_recommendations": [
      {
        "hypothesis_id": "H1",
        "candidate": {
          "id": "drug_ursodiol",
          "name": "Ursodiol"
        },
        "score": 0.72,
        "graph_snapshot_ref": "GE_H1_round4",
        "key_assumptions": [
          "存在 Drug→Target→Pathway→Disease 的有效机制链",
          "尽管存在风险，仍有治疗潜力"
        ],
        "caveats": [
          "存在显著的安全性风险",
          "风险可能抵消药物的净效益"
        ],
        "confidence": "medium"
      }
    ],
    "audit_report": {
      "decisive_graph_motifs": [
        {
          "pattern": "Drug→Target→Pathway→Disease",
          "reason": "机制链有效且支持风险认知"
        }
      ],
      "remaining_gaps": [
        "冲突热点：需对风险的充分检验及量化验证"
      ]
    },
    "seed_retrospective": {
      "batches": [],
      "lessons": []
    },
    "prompt_patches": [],
    "heuristics": []
  },
  "experience_used": true,
  "explorer_prompt": "List drugs that could be indicated for the rare disease 'Neonatal cholestasis'. Return only names.\n\n# Prior guidance for Explorer:\n- 确保查询一致性，并涵盖药物作用机制与胆汁流动补充的不同路径。\n\n# Heuristics:\n- When 胆汁淤积证据较弱: then 优先考虑药物作用机制的连贯性与旁路风险的验证。\n- When 不良反应未明确: then 进一步收集临床数据以评估疗效安全比例。"
}